Sana Biotechnology (SANA) Fundamental Analysis: Revenue, Earnings & Valuation

5.19 / 10

Netural

Fundamental assessment is neutral, with a 5.2/10 score. Strengths include strong cash‑to‑market (Cash‑MV), high inventory turnover, robust fixed‑asset turnover and 134% YoY revenue growth. Weaknesses are low gross profit margin, modest PB‑ROE, negative revenue‑to‑market and high income‑tax ratio.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score1/3

Weight11.82%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.06%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.68%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.11%

1M Return-0.63%

PB-ROE

Value1.13

Score1/3

Weight13.14%

1M Return5.29%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.90%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.02%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.07%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight33.29%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight13.93%

1M Return5.94%

Is SANA fundamentally strong?

SANA scores 5.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -118.70% ROE, 0.00% net margin, -2.93 P/E ratio, 4.45 P/B ratio, and 17.24% earnings growth, these metrics solidify its Netural investment rating.